In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Naurex grosses $38mm in Series B round led by Baxter Ventures; adds $25mm

Executive Summary

First-time investor Baxter Ventures has led a $38mm Series B financing for Naurex Inc. (developing CNS compounds that safely modulate the NMDA receptor). Another new backer Savitr Capital participated along with returning shareholders Adams Street Partners, Latterell Venture Partners, Genesys Capital, PathoCapital, Druid BioVentures, Northwestern University, H. Lundbeck AS, Takeda Ventures, Shire PLC, and private investors.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies